Vascular and Neuronal Protection Induced by the Ocular Administration of Nerve Growth Factor in Diabetic-Induced Rat Encephalopathy

CNS Neuroscience and Therapeutics

Volumn 19, Issue 5, 2013, Pages 307-318

  Tirassa, Paola ^a   Maccarone, Mattia ^a   Florenzano, Fulvio ^b   Cartolano, Sara ^a   De Nicolò, Sara ^a  

^a CNR   (Italy)

^b EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

Author keywords

Diabetes; Forebrain; Neuroprotection; Ocular NGF; ProNGF

Indexed keywords

NERVE GROWTH FACTOR RECEPTOR; NEUROPROTECTIVE AGENT; NEUROTROPHIN; PROTEIN TYROSINE KINASE A; RECOMBINANT NERVE GROWTH FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN ATROPHY; BRAIN BLOOD VESSEL; BRAIN DISEASE; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FOREBRAIN; MALE; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; RAT; UPREGULATION; WESTERN BLOTTING;

ADMINISTRATION, OPHTHALMIC; ANIMALS; CELL SURVIVAL; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; HIPPOCAMPUS; MALE; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, NERVE GROWTH FACTOR; RECEPTOR, TRKA; RECEPTORS, NERVE GROWTH FACTOR; SEPTUM OF BRAIN; STREPTOZOCIN;

EID: 84876795545     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12085     Document Type: Article

References (35)

1. Northam EA, Rankins D, Lin A, et al. Central nervous system function in youth with type 1 diabetes 12 years after disease onset. Diabetes Care 2009;32:445-450.
2. van Duinkerken E, Klein M, Schoonenboom NS, et al. Functional brain connectivity and neurocognitive functioning in patients with long-standing type 1 diabetes with and without microvascular complications: a magnetoencephalography study. Diabetes 2009;58:2335-2343.
3. Sima AA. Encephalopathies: the emerging diabetic complications. Acta Diabetol 2010;47:279-293.
4. Revsin Y, Rekers NV, Louwe MC, et al. Glucocorticoid receptor blockade normalizes hippocampal alterations and cognitive impairment in streptozotocin-induced type 1 diabetes mice. Neuropsychopharmacology 2009;34:747-758.
5. Sima AA, Zhang W, Muzik O, et al. Sequential abnormalities in type 1 diabetic encephalopathy and the effects of C-Peptide. Rev Diabet Stud 2009;6:211-222.
6. Aloe L, Tirassa P, Bracci-Laudiero L. Nerve growth factor in neurological and non-neurological diseases: basic findings and emerging pharmacological prospectives. Curr Pharm Des 2001;7:113-123.
7. Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 2001;24:1217-1281.
8. Schulte-Herbruggen O, Jockers-Scherubl MC, Hellweg R. Neurotrophins: from pathophysiology to treatment in Alzheimer's disease. Curr Alzheimer Res 2008;5:38-44.
9. Apfel SC. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? Int Rev Neurobiol 2002;50:393-413.
10. Fahnestock M, Michalski B, Xu B, et al. The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease. Mol Cell Neurosci 2001;18:210-220.
11. Bruno MA, Cuello AC. Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. Proc Natl Acad Sci USA 2006;103:6735-6740.
12. Masoudi R, Ioannou MS, Coughlin MD, et al. Biological activity of nerve growth factor precursor is dependent upon relative levels of its receptors. J Biol Chem 2009;284:18424-18433.
13. Cuello AC, Bruno MA, Allard S, et al. Cholinergic involvement in Alzheimer's disease. A link with NGF maturation and degradation. J Mol Neurosci 2010;40:230-235.
14. Bruno MA, Leon WC, Fragoso G, et al. Amyloid beta-induced nerve growth factor dysmetabolism in Alzheimer disease. J Neuropathol Exp Neurol 2009;68:857-869.
15. Aloe L, Tirassa P, Lambiase A. The topical application of nerve growth factor as a pharmacological tool for human corneal and skin ulcers. Pharmacol Res 2008;57:253-258.
16. Calza A, Florenzano F, Pellegrini D, et al. Time-dependent activation of c-fos in limbic brain areas by ocular administration of nerve growth factor in adult rats. J Ocul Pharmacol Ther 2011;27:209-218.
17. Di Fausto V, Fiore M, Tirassa P, et al. Eye drop NGF administration promotes the recovery of chemically injured cholinergic neurons of adult mouse forebrain. Eur J Neurosci 2007;26:2473-2480.
18. Tirassa P, Triaca V, Amendola T, et al. EGF and NGF injected into the brain of old mice enhance BDNF and ChAT in proliferating subventricular zone. J Neurosci Res 2003;72:557-564.
19. Lambiase A, Tirassa P, Micera A, et al. Pharmacokinetics of conjunctivally applied nerve growth factor in the retina and optic nerve of adult rats. Invest Ophthalmol Vis Sci 2005;46:3800-3806.
20. Vereczki V, Koves K, Csaki A, et al. Distribution of hypothalamic, hippocampal and other limbic peptidergic neuronal cell bodies giving rise to retinopetal fibers: anterograde and retrograde tracing and neuropeptide immunohistochemical studies. Neuroscience 2006;140:1089-1100.
21. Bocchini V, Angeletti PU. The nerve growth factor: purification as a 30, 000-molecular-weight protein. Proc Natl Acad Sci USA 1969;64:787-794.
22. Paxinos G, Watson C. The rat brain in stereotaxic coordinates, 3rd edn. Australia: Academic Press, 1997.
23. Mouton P. Principles and Practices of Unbiased Stereology: An Introduction for Bioscientists, Baltimore: The Johns Hopkins University Press, 2002.
24. Fortress AM, Buhusi M, Helke KL, et al. Cholinergic Degeneration and Alterations in the TrkA and p75NTR Balance as a Result of Pro-NGF Injection into Aged Rats. J Aging Res 2011;2011:460543.
25. Cuello AC, Bruno MA, Bell KF. NGF-cholinergic dependency in brain aging, MCI and Alzheimer's disease. Curr Alzheimer Res 2007;4:351-358.
26. Mufson EJ, Ma SY, Cochran EJ, et al. Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol 2000;427:19-30.
27. Peng S, Wuu J, Mufson EJ, et al. Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer disease. J Neuropathol Exp Neurol 2004;63:641-649.
28. Tirassa P. The nerve growth factor administrated as eye drops activates mature and precursor cells in subventricular zone of adult rats. Arch Ital Biol 2011;149:205-213.
29. Pezet S, Malcangio M. Brain-derived neurotrophic factor as a drug target for CNS disorders. Expert Opin Ther Targets 2004;8:391-399.
30. Nitta A, Murai R, Suzuki N, et al. Diabetic neuropathies in brain are induced by deficiency of BDNF. Neurotoxicol Teratol 2002;24:695-701.
31. Moser KV, Reindl M, Blasig I, et al. Brain capillary endothelial cells proliferate in response to NGF, express NGF receptors and secrete NGF after inflammation. Brain Res 2004;1017:53-60.
32. Moser KV, Stockl P, Humpel C. Cholinergic neurons degenerate when exposed to conditioned medium of primary rat brain capillary endothelial cells: counteraction by NGF, MK-801 and inflammation. Exp Gerontol 2006;41:609-618.
33. Huber JD, VanGilder RL, Houser KA. Streptozotocin-induced diabetes progressively increases blood-brain barrier permeability in specific brain regions in rats. Am J Physiol Heart Circ Physiol 2006;291:H2660-H2668.
34. Georgescu A. Vascular dysfunction in diabetes: the endothelial progenitor cells as new therapeutic strategy. World J Diabetes 2011;2:92-97.
35. Graiani G, Emanueli C, Desortes E, et al. Nerve growth factor promotes reparative angiogenesis and inhibits endothelial apoptosis in cutaneous wounds of Type 1 diabetic mice. Diabetologia 2004;47:1047-1054.